Global Veterinary Pharmaceuticals Market Size By Type (Veterinary Biological Drugs, Veterinary Preparations), By Application (Poultry, Pets), By Region, And Segment Forecasts, 2023 to 2032

The Global Veterinary Pharmaceuticals Market was valued at USD 37.9 billion in 2023 and is projected to surpass USD 63.4 billion by 2031, expanding at a CAGR of 6.7% during the forecast period of 2023 to 2031. The market is driven by rising pet ownership, increasing incidence of zoonotic and chronic diseases in animals, and advancements in veterinary medicine. Growing awareness of animal health, coupled with higher veterinary healthcare expenditures and the introduction of innovative drugs, is accelerating market expansion globally.

Drivers

1. Rising Pet Ownership and Companion Animal Care

The increasing number of pet adoptions, especially in urban areas, is contributing to higher demand for veterinary pharmaceuticals. Pet owners are more inclined to invest in preventive and therapeutic treatments, thereby fueling the market.

2. Surge in Zoonotic Disease Cases

A global uptick in zoonotic diseases like rabies, brucellosis, and leptospirosis is prompting governments and veterinary institutions to enhance pharmaceutical preparedness, boosting product uptake.

3. Advancements in Drug Delivery and Formulation

Technological innovations in drug delivery methods—such as chewables, long-acting injectables, and oral suspensions—are improving compliance and therapeutic outcomes in animals.

Restraints

1. Regulatory Hurdles and Long Approval Timelines

Veterinary drugs face rigorous regulatory requirements before approval, leading to longer development cycles and elevated R&D costs.

2. Limited Access in Developing Regions

In many emerging markets, inadequate veterinary infrastructure and lower awareness about animal healthcare limit the penetration of advanced pharmaceuticals.

Opportunity

1. Expansion of Livestock Sector in Emerging Economies

Countries in Asia-Pacific and Latin America are experiencing rapid growth in livestock farming. This trend presents significant opportunities for veterinary pharmaceutical manufacturers to offer disease prevention and productivity-enhancing products.

2. Increasing Focus on Preventive Care and Vaccination

Growing emphasis on disease prevention, especially through vaccination programs and parasite control, is paving the way for strong growth in the veterinary vaccine and parasiticide segments.

Market by System Type Insights

Pharmaceuticals for Companion Animals dominated the market in 2023, driven by increased pet spending, the humanization of pets, and the rise in chronic disease treatment options such as arthritis and diabetes medications. Meanwhile, pharmaceuticals for livestock animals are experiencing steady growth, especially in countries prioritizing food security and livestock productivity.

Market by End-use Insights

Veterinary Hospitals and Clinics emerged as the leading end-use segment, accounting for over 45% of total market revenue in 2023. These facilities serve as the primary centers for diagnosis and treatment. The Retail Pharmacies segment is also gaining traction, propelled by online pharmacies and the increasing availability of prescription and OTC veterinary drugs.

Market by Regional Insights

North America dominated the market in 2023 due to its advanced veterinary healthcare infrastructure, strong pet ownership trends, and favorable reimbursement frameworks. However, Asia-Pacific is expected to exhibit the highest growth rate during the forecast period, fueled by a rising livestock population, growing awareness, and supportive government animal health initiatives.

Competitive Scenario

Key players operating in the global veterinary pharmaceuticals market include Zoetis Inc., Boehringer Ingelheim Animal Health, Elanco Animal Health Incorporated, Merck Animal Health, Ceva Santé Animale, Virbac, Vetoquinol S.A., Dechra Pharmaceuticals PLC, Norbrook Laboratories, and Bayer Animal Health. These companies are focusing on product innovation, global expansion, and strategic acquisitions.

Key Developments:

In 2023, Zoetis launched a long-acting monoclonal antibody for treating chronic canine osteoarthritis.

In 2024, Elanco partnered with regional veterinary networks in Asia to expand its distribution footprint.

In 2025, Merck Animal Health acquired a veterinary biologics firm to strengthen its vaccine portfolio.

Scope of Work – Global Veterinary Pharmaceuticals Market

FAQs

1) What is the current market size of the Global Veterinary Pharmaceuticals Market?

The market was valued at USD 37.9 billion in 2023.

2) What is the major growth driver of the Global Veterinary Pharmaceuticals Market?

The major growth driver is the rising global pet population and increased demand for disease prevention and treatment in animals.

3) Which is the largest region during the forecast period in the Global Veterinary Pharmaceuticals Market?

North America is currently the largest region; however, Asia-Pacific is expected to grow at the fastest rate.

4) Which segment accounted for the largest market share in the Global Veterinary Pharmaceuticals Market?

The Companion Animals segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Veterinary Pharmaceuticals Market?

Zoetis, Merck Animal Health, Elanco, Boehringer Ingelheim, and Virbac are among the leading players.